BiotechTube

mRNA-1083

Phase 3Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2, Influenza

Conditions

SARS-CoV-2, Influenza

Trial Timeline

Oct 19, 2023 → May 28, 2024

NCT ID
NCT06097273

About mRNA-1083

mRNA-1083 is a phase 3 stage product being developed by Moderna for SARS-CoV-2, Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT06097273. Target conditions include SARS-CoV-2, Influenza.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2, Influenza were approved

Approved (4) Terminated (1) Active (16)
✅mRNA-1273 Variant-containing FormulationModernaApproved
✅mRNA-1273ModernaApproved
✅AZD1222AstraZenecaApproved
✅BNT162b2PfizerApproved
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3

Clinical Trials (3)

NCT IDPhaseStatus
NCT06694389Phase 3Completed
NCT06508320Phase 2Completed
NCT06097273Phase 3Completed

Competing Products

20 competing products in SARS-CoV-2, Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0